To address the function of IL-25 in tumor progression and metastasis, MMTV-PyMT mice were treated with an anti-IL-25 antibody or control antibody (Rat IgG) at the onset time of primary tumors (~4–5 week of age). The gene discussed is IL25; the disease is neoplasm.